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Vaccinia virus (VACV) encodes multiple proteins to evade host innate immunity, including B14,
a virulence factor that binds to the inhibitor of kB kinase b (IKKb) and blocks nuclear factor kB
(NF-kB) activation. B14 shares 95 % amino acid identity with the 183 protein encoded by
modified virus Ankara (MVA), an attenuated VACV strain being developed as a vaccine vector. To
evaluate whether the immunogenicity of MVA might be increased by manipulation of MVA
immunomodulatory proteins, the MVA counterpart of B14, protein 183, was characterized. Unlike
B14, protein 183 was unstable in eukaryotic cells unless proteasome-mediated protein
degradation was inhibited. Furthermore, 183 did not inhibit NF-kB activation in response to
cytokine stimulation, and did not restore the virulence of VACV strain Western Reserve lacking
gene B14R. The instability and non-functionality of 183 are probably explained by a deletion of
6 aa within a-helix 6 of the B14 crystal structure.
Vaccinia virus (VACV) is the best-studied member of the
family Poxviridae; it is a double-stranded DNA virus that
replicates in the cytoplasm of host cells (Moss, 2007).
VACV was used as the vaccine to eradicate smallpox
(Fenner et al., 1988) and thereafter has continued to be
studied due to its development as a vaccine for other
infectious diseases (Smith et al., 1983), and because it is an
excellent model for studying virus–host interactions.
Although immunoprophylaxis with VACV led to eradica-
tion of smallpox, VACV had an imperfect safety record
(Lane et al., 1969) and it was recognized that the safety
profile needed improvement if VACV was to be used again
widely for human vaccination. One strategy to improve
safety was to passage VACV strains repeatedly in cell
culture until attenuation was achieved, the classical manner
in which live-attenuated vaccines were developed for
yellow fever, polio, measles, mumps and rubella. In this
way, the LC16m8 strain was derived from VACV Lister in
Japan (Hashizume et al., 1985), and modified virus Ankara
(MVA) was derived from VACV chorioallantois virus
Ankara (CVA) in Germany by more than 570 passages in
chicken embryo fibroblasts (CEFs) (Mayr & Munz, 1964;
Stickl et al., 1974; Mayr et al., 1978). During this serial
passage, MVA incurred six major deletions (Meyer et al.,
1991) and many smaller mutations (Antoine et al., 1998)
compared with the parental CVA (Meisinger-Henschel
et al., 2007), and developed a severe restriction in host
range so that it is unable to replicate in most mammalian
cells (Meyer et al., 1991; Sutter & Moss, 1992). In the later
stages of the smallpox-eradication campaign, MVA was
used as a smallpox vaccine in over 120 000 individuals
without complications (Stickl et al., 1974; Mayr et al., 1978;
Mahnel & Mayr, 1994). MVA lacks many immunomodu-
lators that are present in other strains of VACV (Antoine
et al., 1998; Blanchard et al., 1998), but other immuno-
modulators remain and deletion of two of these, B15 and
A41, enhanced MVA immunogenicity (Staib et al., 2005;
Clark et al., 2006). This paper concerns MVA protein 183,
the counterpart of VACV strain Western Reserve (WR)
protein B14 (Chen et al., 2006).
VACV WR protein B14 is expressed early after infection in
the cytoplasm and is non-essential for virus replication in
cell culture (Chen et al., 2006). However, a B14R deletion
mutant (vDB14) was attenuated in a mouse intradermal
(i.d.) infection model and affected the inflammatory
response to infection (Chen et al., 2006). Further study
demonstrated that B14 inhibits nuclear factor kB (NF-kB)
activation by binding to the inhibitor of kB kinase (IKK)
complex via the IKKb subunit (Chen et al., 2008). The
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crystal structure of B14 was solved and revealed a B-cell
lymphoma (Bcl)-2 protein fold, despite B14 lacking
sequence similarity to Bcl-2 proteins, a family of proteins
that regulate apoptosis. Anti-apoptotic Bcl-2 proteins
contain a surface groove that binds the BH3 peptide of
pro-apoptotic Bcl-2 family members and thereby neutra-
lizes pro-apoptotic activity. In comparison, B14 lacked a
surface groove and was not anti-apoptotic (Graham et al.,
2008). Given that deletion of B14R from VACV WR
increased the recruitment of leukocytes to the site of
infection (Chen et al., 2006), it was hypothesized that
deletion of gene 183R might increase MVA immunogeni-
city and increase its potency as a vaccine.
B14 and 183 share 95 % amino acid identity, and there are
three sequence differences (Fig. 1a). First, in B14 a-helix 1
(a1; Fig. 1b), there is a conservative R27K substitution in
MVA 183 and the same change is seen in CVA, rabbitpox
virus Utrecht (a VACV strain) and VACV strains Acambis
3 and 3737. Second, in B14 a-helix 5, there is another
conservative substitution (A84V) in MVA. In different
VACV strains and other orthopoxviruses, alanine, valine or
threonine is found at this position (Fig. 1b). Third, and
most notably, there is a 6 aa deletion in MVA 183
corresponding to B14 a-helix 6 (a6; Fig. 1b), and this
deletion is not found in any other VACV strains or
orthopoxviruses. The central position of this helix in the
B14 structure suggests that this deletion in 183 might affect
the overall fold of the protein. In contrast, the other amino
acid substitutions are unlikely to do so.
To examine whether protein 183 behaves in an analogous
manner to B14 as an inhibitor of NF-kB activation, the
183R gene including DNA encoding an N-terminal FLAG
tag was cloned into the mammalian expression vector
pCI (Promega) downstream of a human cytomegalovirus
immediate-early promoter. HEK 293T cells (Chen et al.,
2008) were transfected with a reporter plasmid containing
firefly luciferase attached to an NF-kB-responsive pro-
moter (Chen et al., 2008), an internal control containing
Renilla luciferase linked to the thymidine kinase promoter
(Chen et al., 2008), and either pCI or pCI encoding FLAG-
tagged B14 or 183 (Fig. 2a). After 18 h, the transfected cells
were stimulated with tumour necrosis factor alpha (TNF-a;
Peprotech) for 8 h. NF-kB activation was assessed by firefly
luciferase activity and normalized by Renilla luciferase
activity. Triplicate samples were collected and data are
expressed as the mean fold induction relative to pCI.
Whilst B14 inhibited NF-kB activation as expected, MVA
183 had no such activity (Fig. 2a). To compare levels of
B14 and 183 protein expression, cell lysates from
the reporter assays were analysed by immunoblotting
with anti-FLAG (Sigma) and anti-a-tubulin (Upstate
Biotechnology) mAbs (Fig. 2b). B14 was easily detectable,
whereas 183 was not. However, after TNF-a treatment, the
level of 183 increased for unknown reasons. Blotting with
an anti-a-tubulin mAb confirmed equal loading of
samples. It appeared, therefore, that 183 was unstable,
but stability was increased by activation of the signalling
pathway leading from TNF-a to NF-kB activation.
Nonetheless, despite 183 expression being detectable after
TNF-a stimulation, under the conditions tested it was
unable to inhibit NF-kB activation.
MVA does not replicate in many mammalian cell lines and
is avirulent in mice. Therefore, to investigate the role of
MVA 183 in virus virulence, the 183R gene was inserted
into VACV strain WR lacking B14R, vDB14 (Chen et al.,
2006), and the virulence of the recombinant virus, vDB14-
MVA183, was measured in a murine i.d. model (Tscharke
& Smith, 1999). A pSJH7-based plasmid (Hughes et al.,
1991) containing the 183R open reading frame flanked by
250 bp of WR genomic DNA upstream and downstream of
B14R was transfected into RK-13 cells (European Collec-
tion of Cell Cultures; ECACC) that were infected with
vDB14. A recombinant virus containing MVA 183, vDB14-
MVA183, was selected by transient dominant selection
(Falkner & Moss, 1990) and PCR analysis confirmed that
vDB14-MVA183 contained the correct genome structure at
the B14R/183R locus (see Supplementary Fig. S1, available
Fig. 1. B14 structure. (a) Alignment of proteins WR B14 and MVA
183. Positions of divergence are shown in bold and underlined.
The positions of the a-helices of the B14 crystal structure are
shown above the alignment and are coloured from N to C terminus
as shown in the three-dimensional structure in (b). (b) Ribbon
representation of the crystal structure of B14. a-Helices are
marked by sequence from N to C terminus and are coloured from
blue (N terminus) to magenta (C terminus). The changes in 183
compared with B14 are shown underlined and in bold, including
the REISAI motif that is deleted in 183.
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in JGV Online). vDB14-MVA183 was purified in parallel
with viruses vB14 (wild-type, WR) and vDB14 (Chen et al.,
2006) by sedimentation through a sucrose cushion, and
virus infectivity was titrated on BS-C-1 cells (ECACC).
Groups of female C57Bl/6 mice, between 6 and 8 weeks old
(Harlan), were anaesthetized and inoculated with each
virus into each ear pinna (Tscharke & Smith, 1999;
Tscharke et al., 2002). Titres of inocula were confirmed
by plaque assay. Animals were examined daily and the
diameter of lesions at the inoculation site was measured
using a micrometer. vDB14 induced a smaller lesion size
than wild-type virus and reinsertion of B14R into vDB14
restored lesion size, as reported previously (Chen et al.,
2006). In contrast, insertion of 183R into vDB14 did not
alter lesion size (Fig. 3a). Therefore, 183 does not
contribute to virulence in this model, a conclusion
consistent with the protein being unstable and unable to
inhibit NF-kB activation in cell culture.
To examine 183 expression in infected cells, lysates from
CEFs infected with MVA or vDB14-MVA183 were analysed
by immunoblotting using the anti-B14 polyclonal antibody
(Chen et al., 2006) and mouse mAbs against D8 (a VACV
late protein) (Parkinson & Smith, 1994) and a-tubulin
(Fig. 3b). As before, although B14 produced by VACV WR
was detected easily, MVA 183 was not detected in cells
infected with MVA or vDB14-MVA183. This difference was
unlikely to be due to altered transcription of gene 183R, as
the nucleotide sequence upstream of MVA 183R was the
same in WR B14R, and so the difference probably reflected
protein instability as noted above (Fig. 2b). A major
pathway for the removal of labile proteins in eukaryotic
cells is via ubiquitination and degradation by the protea-
some. To assess whether protein 183 was being degraded
by this mechanism, a proteasome inhibitor (MG132;
Satheshkumar et al., 2009) was added to cells prior to
and throughout infection. MG132 is a short oligopeptidic
sequence with an aldehyde electrophilic structure at the C
terminus. It blocks multiple active sites in the proteasome
Fig. 2. Protein 183 does not inhibit NF-kB activation by TNF-a.
(a) HEK 293T cells were transfected with either pCI or pCI contain-
ing FLAG-tagged B14 or 183 (pB14f and p183f) and a luciferase
NF-kB reporter plasmid for 18 h. Cells were then stimulated with
50 ng TNF-a ml”1 for 8 h and luminescence was assessed as
described previously (Chen et al., 2008). The assay was carried out
in triplicate and the error bars represent SD from the mean. (b) A
small aliquot of the cell lysates was retained and analysed by
immunoblotting with anti-FLAG and anti-a-tubulin mAbs. The
positions of molecular mass markers in kDa are indicated.
Fig. 3. (a) Measurement of virulence of VACV WR strains with or
without MVA 183. (a) Groups of eight C57Bl/6 mice were infected
i.d. with 104 p.f.u. vB14 (&), vDB14 (m) or vDB14-MVA183 ($)
in 10 ml PBS and the lesion diameter was recorded daily. Error
bars represent SEM. (b) Expression of B14 and 183 proteins after
infection of CEFs. CEFs were infected at 10 p.f.u. per cell with
VB14, vDB14-MVA183 or MVA. Where indicated, cells were
treated with MG132 (10 mM) for 1.5 h before and throughout
infection. Infected cells were incubated for 8 h before lysis and
analysis by SDS-PAGE and immunoblotting with anti-B14, anti-D8
and anti-a-tubulin antibodies. The positions of molecular mass
markers in kDa are indicated.
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by forming transition-state analogues via interacting with a
catalytic hydroxyl/thiol group to form a reversible hemi
(thio)acetal. In the presence of MG132, protein 183
expression from MVA or vDB14-MVA183 was detected
and was similar in each case (Fig. 3b). This showed that 183
was labile and degraded by the proteasome. It also
indicated that additional factors expressed by VACV WR
were unable to stabilize protein 183.
Analysis of VACV protein D8 expression levels in these
cells showed a substantial decrease in the presence of
MG132. This observation was in accord with the report
that MG132 blocks a post-entry step in VACV replica-
tion (Satheshkumar et al., 2009). After virus entry and
uncoating, viral DNA synthesis is prevented so that
virus intermediate- and late-gene expression is inhibited
(Satheshkumar et al., 2009). D8 is a late protein and is
therefore reduced considerably by MG132. This reduction
in D8 expression also served as a control, showing that
MG132 was inhibiting proteasome activity.
Several lines of evidence indicate that MVA 183 is a labile
protein. First, following transfection of mammalian cells
with plasmids encoding 183, the protein was not detected,
whereas B14 was. Second, after infection of avian cells by
MVA or a VACV WR virus encoding MVA 183, the 183
protein was not detectable unless the proteasome was
inhibited by MG132. Third, attempts to express protein
183 in Escherichia coli under conditions that yielded stable,
soluble B14 protein that was used for protein crystal-
lography (Graham et al., 2008) gave only low yields of
insoluble 183 (data not shown). Therefore, 183 is a labile
protein and the probable cause is deletion of the REISAI
motif in the B14 a6 helix. This deletion is found only in
MVA and in no other VACV strain, including the parental
virus CVA, and so arose during MVA passage in CEFs. The
observation that MVA 183 does not inhibit NK-kB
activation may explain, at least in part, why MVA infection
activates NF-kB in contrast to other VACV strains (Oie &
Pickup, 2001). Interestingly, protein 183 was stabilized
after treatment of cells with TNF-a. Possible explanations
for this are alterations to the proteasome-mediated
degradation of proteins after TNF-a stimulation, or that
a component of the TNF-a-induced signalling pathway
leading to NF-kB activation can somehow stabilize the 183
protein once the pathway is activated. However, if the latter
were true, it is notable that, even when 183 is present, at the
levels tested it did not inhibit NF-kB activation. It is also
formally possible, but less likely, that TNF-a treatment is
affecting 183 mRNA levels.
The original bioinformatic analysis of the MVA genome
recorded open reading frames that were retained, deleted
or disrupted by mutation compared with other VACV
strains (Antoine et al., 1998), but the functional con-
sequences of smaller mutations, such as those noted here
for protein 183, were unknown. Here we demonstrate that,
although MVA protein 183 shares 95 % amino acid
sequence identity with protein B14 from VACV strain
WR, it is unstable and lacks the functions assigned to
protein B14, such as inhibition of NF-kB activation and
contribution to virus virulence. Other MVA genes
encoding immunomodulatory proteins with small dele-
tions or mutations relative to counterparts in other VACV
strains are as yet uncharacterized and these changes may
have important functional consequences. Attempts to
increase the immunogenicity of MVA by engineering or
deletion of genes encoding immunomodulators should be
informed by knowledge of whether the encoded protein is
functional, and priority should be given to engineering
genes known to encode functional proteins.
In summary, MVA protein 183 is a non-functional
counterpart of VACV WR protein B14 and neither inhibits
NF-kB activation following addition of TNF-a, nor con-
tributes to VACV strain WR virulence. The loss of function is
probably attributable to a 6 aa deletion within the a6 helix of
the Bcl-2 fold and it is unlikely that removal of this gene from
the MVA genome will enhance MVA immunogenicity.
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